155 related articles for article (PubMed ID: 35894461)
1. Naturally Occurring Compounds as Potential Inhibitors of Epidermal Growth Factor Receptors (EGFRs).
Oktavia L; Fuad AM; Senjaya SK; Yuliyawati Y
Comb Chem High Throughput Screen; 2023; 26(6):1093-1107. PubMed ID: 35894461
[TBL] [Abstract][Full Text] [Related]
2. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
Wang X; Xu L; Lao Y; Zhang H; Xu H
Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
[TBL] [Abstract][Full Text] [Related]
3. Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight.
Damare R; Engle K; Kumar G
Phytother Res; 2024 May; 38(5):2406-2447. PubMed ID: 38433568
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective.
Patel HM; Rane R; Thapliyal N; Palkar M; Shaikh M; Karpoormath R
Anticancer Agents Med Chem; 2015; 15(8):988-1011. PubMed ID: 25763933
[TBL] [Abstract][Full Text] [Related]
5. Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents.
Nandi S; Dey R; Samadder A; Saxena A; Saxena AK
Curr Med Chem; 2022; 29(2):212-234. PubMed ID: 33655823
[TBL] [Abstract][Full Text] [Related]
6. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
Cao C; Lu S; Sowa A; Kivlin R; Amaral A; Chu W; Yang H; Di W; Wan Y
Cancer Lett; 2008 Aug; 266(2):249-62. PubMed ID: 18400375
[TBL] [Abstract][Full Text] [Related]
7. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.
Liang Y; Zhang T; Zhang J
Pharmacol Res; 2020 Nov; 161():105164. PubMed ID: 32846211
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
Liu YC; Tsai JJ; Weng YS; Hsu FT
Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
[TBL] [Abstract][Full Text] [Related]
9. Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities.
Zubair T; Bandyopadhyay D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768973
[TBL] [Abstract][Full Text] [Related]
10. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
11. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
12. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.
Sabbah DA; Hajjo R; Sweidan K
Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological background of EGFR targeting.
Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
[TBL] [Abstract][Full Text] [Related]
14. The story of EGFR: from signaling pathways to a potent anticancer target.
Ramani S; Samant S; Manohar SM
Future Med Chem; 2022 Sep; 14(17):1267-1288. PubMed ID: 35880513
[TBL] [Abstract][Full Text] [Related]
15. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
[TBL] [Abstract][Full Text] [Related]
16. EGFR inhibitors and autophagy in cancer treatment.
Cui J; Hu YF; Feng XM; Tian T; Guo YH; Ma JW; Nan KJ; Zhang HY
Tumour Biol; 2014 Dec; 35(12):11701-9. PubMed ID: 25293518
[TBL] [Abstract][Full Text] [Related]
17. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
[TBL] [Abstract][Full Text] [Related]
18. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.
Itoh T; Hatano R; Horimoto Y; Yamada T; Song D; Otsuka H; Shirakawa Y; Mastuoka S; Iwao N; Aune TM; Dang NH; Kaneko Y; Okumura K; Morimoto C; Ohnuma K
Cell Death Dis; 2021 May; 12(6):520. PubMed ID: 34021125
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
[TBL] [Abstract][Full Text] [Related]
20. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
